M. Scott Harris

M. Scott Harris, M.D., is currently the Chief Medical Officer at Altimmune. Prior to this, they served as the Co-Founder and Chief Medical Officer of Lyric Pharmaceuticals from November 2013 to May 2018, and as Chief Medical Officer of Avaxia Biologics from January 2012 to December 2015.

Dr. Harris has over 15 years of experience in the pharmaceutical industry, with a focus on gastrointestinal (GI) diseases. M. has played a pivotal role in the development of several important GI therapeutics, including Lyric's lead product for enteral feeding intolerance (EFI) and Avaxia's lead product for inflammatory bowel disease (IBD).

Dr. Harris received their medical degree from the University of Pennsylvania School of Medicine. M. completed their residency in Internal Medicine at Massachusetts General Hospital and their fellowship in Gastroenterology at Harvard Medical School.

M. Scott Harris is an MD who attended Harvard Medical School. M. also has a BA in Chemistry from Harvard University and an M.S. in Administrative Medicine and Population Health from the University of Wisconsin Medical School.

They work with Sybil Tasker - Chief Medical Officer, Ori Solomon - Outside General Counsel, and José Ochoa - Chief Business Officer. M. Scott Harris reports to Vipin K. Garg, President & CEO.